Abstract
Context.— The 21-gene recurrence score (RS) provides a probability of distant recurrence for estrogen receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancers. The utility of RS for rarer histologic subtypes of breast cancer is uncertain. Objective.— To determine the distribution of RS among various histologic subtypes using a population database. Design.— Women between the ages of 18 and 75 with estrogen receptor-positive, HER2-negative breast cancer and known RS results were identified using the Surveillance, Epidemiology, and End Results database. Recurrence scores were categorized into risk groups using both traditional and Trial Assigning Individualized Options for Treatment cutoffs. Multivariable logistic regression was used to determine factors associated with high-risk RS. Results.— We identified 45 618 patients with stage I to III, estrogen receptor–positive, HER2-negative breast cancer who had RS available. Overall, 3087 (7%) and 6337 (14%) of cancers were class...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
